Cancer & Cancer Genetics
One in four people will develop cancer sometime during his or her lifetime. As daunting as this statistic is, research in cancer and cancer genetics offers new hope that the battle against this killer can be won. Our researchers are pushing the boundaries of technology and medicine, developing new diagnostics and new therapies specifically targeting cancer on Long Island. The new strategic weapons to be deployed are the very latest in emerging technologies that empower a new generation of cancer researchers.
Cancer & Cancer Genetics is the research arm of the Cancer Institute of Long Island at Stony Brook, a cutting-edge cancer center providing a multidisciplinary approach to basic and clinical cancer research, detection, and analysis, while offering comprehensive care to cancer patients. Our Physician-Scientists training opportunities are unparalleled, offering the clinically-trained MD an exciting environment rich with interaction among cancer biologists, cancer geneticists, structural biologists, and experts in fields of developmental genetics and infectious disease.
ts distinguished faculty have already made milestone discoveries, including the rearrangement of the c-myc oncogene that causes Burkitt's lymphoma; the deregulation of protective tumor suppressors, such as p53, that lead to tumorigenesis; the identification of the importance of the tyrosine kinases, such as Src, in cell growth; and oncogenesis and the mapping of intimate details of the Ras oncogene signaling pathways common to many cancers in humans.
The Brookhaven National Laboratory offers the only site in the nation for Boron-Neutron-Capture Therapy. Researchers from Cancer & Cancer Genetics are working with our partners at BNL to improve killing of cancer cells by Boron-containing molecules that absorb neutrons from the Medical Reactor.
Early Breast Cancer Detection
Advances in imaging are increasing the sensitivity of detection of breast cancer at its earliest stages. Sophisticated epidemiology provides a base for national studies aimed at cancer prevention. The infrastructure on which these translational clinical efforts advance is based on the work of the strong, internationally-recognized cancer biologists, geneticists, and specialists working at the CMM.
Strategic Opportunities for Research
Some of the promising areas of investigation include the identification of new tumor markers through powerful chip technologies, the application of novel genetic ap-proaches to deduce signatures of specific cancers, and the mapping of cancer on Long Island, creating a home advantage for regional analysis of breast and other cancers.